Company intelligence / Profile preview

Molcure

Kawasaki, Kanagawa, Japanmolcure.com ↗

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Molcure has developed a proprietary AI-driven drug discovery platform integrating machine learning, robotics, next-generation sequencing, and a large proprietary database (>1 billion data points) to generate high-affinity antibodies and peptides. The company collaborates with pharmaceutical partners but does not have its own clinical-stage assets publicly disclosed as of June 2025[1][2][3].

Therapeutic areas: Other
Modalities: AntibodyPeptidesBiologic (general platform for biologics)
Industry: Drug Discovery Services

Partnerships

Multiple pharmaceutical companies (not individually named in public sources)[1][2]UTEC – University of Tokyo Edge Capital Partners (investor/supporter)[6]

Beyond the preview

Go deeper on Molcure.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Molcure.

Explore the full profile